Welcome to our dedicated page for Picard Medical news (Ticker: PMI), a resource for investors and traders seeking the latest updates and insights on Picard Medical stock.
Picard Medical, Inc. (NYSE American: PMI) is the parent company of SynCardia Systems, LLC, a medical technology company focused on total artificial heart therapy for patients with advanced and end-stage heart failure. News about Picard Medical often centers on the SynCardia Total Artificial Heart (STAH), which company materials describe as the only commercially available total artificial heart technology for patients with end-stage heart failure and the first artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada.
Readers of this PMI news page can expect coverage of clinical and technology milestones related to the SynCardia Total Artificial Heart and the next-generation, fully implantable Emperor Total Artificial Heart platform. Recent company announcements have highlighted in vitro and in vivo data on the Emperor system, including the first pre-clinical implantations of the fully implantable device, as well as presentations at specialized heart failure and mechanical circulatory support conferences.
Picard Medical’s news flow also includes updates on product enhancements, such as the rollout of FDA-cleared CPC1 Connector Covers designed to provide additional protection and comfort for patients using the SynCardia Total Artificial Heart. Corporate and capital markets developments, including senior secured debt financings, registration statements, and participation in healthcare investor conferences, are disclosed through press releases and corresponding SEC filings.
Investors and clinicians following PMI news can use this page to review company communications on regulatory developments, collaboration agreements for the Emperor platform, clinical data presentations, and broader strategic updates related to total artificial heart technology. The news archive offers a consolidated view of how Picard Medical and SynCardia are advancing their artificial heart platforms and engaging with the heart failure and medical device communities.
Picard Medical (NYSE American: PMI) announced that Dr. Andre Simon, Vice President of Clinical Affairs, will present data on the fully implantable Emperor Total Artificial Heart (TAH) at the 19th EUMS & 11th International Course on Mechanical Circulatory Support, Feb 15–18, 2026 in Barcelona.
The presentation, titled "The Emperor Rises: First In Vitro and In Vivo Evaluation of SynCardia’s Electromechanical Total Artificial Heart," is scheduled for February 16, 2026 at 17:15 CET.
Picard Medical (NYSE American: PMI) and SynCardia will present a DeviceTalks Tuesdays webinar on Feb 3, 2026, covering the Emperor fully implantable total artificial heart.
COO Matt Schuster will review preclinical bench and acute in vivo data focusing on hemodynamic performance, robustness, physiological responsiveness, and system stability.
Picard Medical (NYSE American: PMI) announced on Jan 13, 2026 the launch of a Cruxx to MedTech podcast series focused on the SynCardia Total Artificial Heart (STAH) and the next‑generation fully implantable Emperor device.
The series features a patient survival story and an interview with CEO Patrick NJ Schnegelsberg, who outlines the STAH platform, differentiation versus other approaches, the Company's long‑term vision as an alternative to transplantation, and the commercial opportunity from global donor heart shortages.
The podcast is available for download and streaming on Apple Podcasts, Spotify, Google Podcasts and via Cruxx's website.
Picard Medical (NYSE American: PMI) announced that SynCardia entered a development collaboration with Hydrix on Jan 5, 2026 to advance the Emperor, SynCardia’s next‑generation fully implantable Total Artificial Heart (TAH).
Hydrix will perform an initial development phase through end of 2026 within a staged, multi‑year program that advances through defined engineering verification and regulatory milestones. The arrangement may allow Picard to benefit from Australian R&D tax incentives of approximately 43% of eligible expenditure, subject to qualification and review.
Picard Medical (NYSE American: PMI) announced its management team will attend conferences during the week of the 44th Annual J.P. Morgan Healthcare Conference (JPM week) in San Francisco.
Planned appearances include an invite-only Lifeblood and Goodwin MedTech CEO-Only Forum on January 12, 2026 at the InterContinental, and one-on-one meetings at the LifeSci Advisors 15th Annual Corporate Access Event on January 14, 2026 at The Beacon Grand. Investors may request in-person meetings via LifeSci registration or by contacting the LifeSci representative Eric Ribner at eric@lifesciadvisors.com.
Picard Medical (NYSE American: PMI) will begin incorporating an FDA-cleared accessory, CPC1 “Connector Covers”, into the SynCardia Total Artificial Heart (STAH) design to enhance patient comfort and reinforce device safety and reliability.
The CPC Connector Covers add a protective layer over the metal release buttons on STAH CPC connectors that link SynCardia Drivers to the two pneumatic drive cannulas. The company expects rollout into U.S. clinical practice beginning January 15, 2026. All SynCardia sales and clinical staff have completed required training; SynCardia will provide hospitals with training materials, implementation guidance, and support for existing patients.
Picard Medical (NYSE American: PMI) announced that Patrick NJ Schnegelsberg, CEO of Picard Medical and SynCardia Systems, was elected to the Board of Directors of the Arizona Bioindustry Association (AZBio).
His board term runs through December 2028. SynCardia, headquartered in Tucson for more than two decades, is noted as the developer of the world’s first and only commercially available total artificial heart approved by the U.S. FDA and Health Canada. The appointment is framed as reinforcing Picard Medical’s commitment to Arizona’s life sciences ecosystem and advancing medical technology for patients.
Picard Medical (NYSE American: PMI) announced a private placement financing of up to $50.0 million in senior secured notes due 2028, together with warrants to purchase common stock, with WestPark Capital as sole placement agent.
The company expects to issue an initial $15.0 million principal amount at closing and may fund up to an additional $35.0 million in one or more tranches subject to conditions. Net proceeds are intended for working capital and general corporate purposes. The securities are not registered under the Securities Act and may not be resold in the U.S. absent registration or an exemption.
Picard Medical (NYSE: PMI) rang the New York Stock Exchange Opening Bell on December 18, 2025, marking its transition to the public markets as parent company of SynCardia Systems.
The company is the maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada and said the public listing supports advancing its total artificial heart platform, including the fully implantable Emperor system.
Picard Medical (NYSE American: PMI) announced that a patient has reached 2,900 days (over eight years) of continuous support with the SynCardia Total Artificial Heart (STAH), the longest recorded time a person has lived on an artificial heart.
The company noted the STAH is the world’s first total artificial heart approved by both the U.S. FDA and Health Canada. Picard said the milestone highlights long-term durability and reliability of the STAH and that it is developing Emperor, a next-generation fully implantable artificial heart system to expand access to long-term support worldwide.
FAQ
What is the current stock price of Picard Medical (PMI)?
What is the market cap of Picard Medical (PMI)?
